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Seminars4th Expert Meeting in September 2012 in Montreux, Switzerland. The program reunited
researchers and clinicians from all over the globe and was organized with lectures and seminars
for real-time exchange of latest information. Platelets target victims of autoimmune disease on
their own, participating under physiological conditions in the immune network; these small
cells are more immunologically savvy than previously thought. Currently, researchers focus
their attention on regulatory T and regulatory B cells, ie, cells that might have a decisive impact
on how ITP spontaneously resolves or evolves into chronic disease. Diagnostic criteria and
prognosis are increasingly benefiting from molecular biological tests, and therapy has evolved
with the availability of biosimilar agents and recombinant hormones or blockers of their
receptors.
Semin Hematol 50:S3-S9. C 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.I
mmune thrombocytopenia (ITP) comprises a
heterogeneous group of diseases characterized
by autoimmune-mediated platelet destruction
and impaired thrombopoiesis. Autoimmune diseases
(AID) are being tamed as their underlying mecha-
nisms are understood, and disease-promoting mecha-
nisms of ITP, increasingly extending their activity to
the elderly,1 are largely embedded in basic immunol-
ogy research. Updates in cellular and humoral immun-
ity, as well as the recent revival of the role of innate
immunity,2 translate into clinical studies with the
potential for new treatment protocols. Identification
of platelet biomarkers and possible drug targets takes
advantage of nanotechnology and proteomics, and
the role of microparticles in an array of nonhemato-
logic diseases implies platelet participation in their
pathogenesis. Simple textbook-encrypted knowledge
on platelet turnover has recently been updated3blished by Elsevier Inc.
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identified genetic variants relevant for clinical care.
The 4th Intercontinental Cooperative ITP Study
Group (ICIS) Meeting brought leading experts to a
3-day conference in Switzerland, the essentials of
which decisively contribute to our understanding
of ITP.PLATELET PHYSIOLOGY AND PRIMARILY
NON-IMMUNOLOGIC DETRIMENTAL
IMPACTS
An improved insight into platelet production/
turnover, more specifically in ITP, has come from
flow cytometry and genomics. The immature platelet
fraction can conveniently be assessed using labora-
tory platforms, allowing for particle size discrimina-
tion, and mean absolute immature platelet fraction
provides real-time thrombopoiesis, with or without
treatment.3 Whereas pre- and post-prednisone plate-
let survival in patients with ITP was the same, one
could document an increased platelet production
from megakaryocytes. A portion of small megakar-
yocytes, assigned by conventional hematology as
‘‘young megakaryocytes,’’ may in fact be sick
megakaryocytes.
Platelets, attaining their physiological life end,
undergo apoptosis, which is now known to require
functioning of the apoptotic caspase cascade.4p S3–S9 S3
U.E. Nydegger and L. RischS4These aspartate-specific cysteinyl proteases are prob-
ably not required for platelet generation, nor for
their function. However, it remains acknowledged
that mitochondrial release of pro-apoptotic cyto-
chrome c favors constitutive formation of pro-plate-
let–bearing megakaryocytes.5 Preliminary work
suggests that some of anti-platelet antibodies might
indeed be directed against caspase.Oxidative Stress
As in any autoimmune disease, ITP cannot escape
the harmful impact of free oxygen radicals. Induc-
tion of antioxidants, an effective strategy for combat-
ing various disease states including cancer with its
aberrant metabolism,6 may apply to ITP patients as
well. We now know that reactive oxygen species
(ROS) arise as a result of incomplete reduction of
oxygen within the electron transport chain, with
accumulation of superoxide anion (O2
0), singlet
oxygen (O2), hydrogen peroxide (H2O2), and the
hydroxyl radical (OH). Although these molecules can
act for signaling, they also cause cellular damage,
such as through lipid peroxidation and DNA damage,
which promotes apoptosis and accelerates cell
aging.7 Similarly, reactive nitrogen oxide species
(RNOx or RNS), including peroxynitrite ONOO(-),
ie, powerful nitrating agents, account for nitrative
stress of platelets and are responsible for dismutase
overproduction. Both ROS and RNS thus become
responsible for lipid and protein (proteome) mod-
ifications, and both can be seen at the origin of
immune complex disease involving oxLDL.8
Oxidatively modified proteins are currently
thought to be involved in such autoimmune disorders
as multiple sclerosis, rheumatoid arthritis, and sys-
temic lupus erythematosus. A closer look at these
diseases has allowed the correlation of severity/activ-
ity with the extent of oxidative stress and pinned
down aldehyd residues as post-translationally modi-
fied reactive proteins.
The link of these situations to ITP comes from the
cDNA microarray analysis finding that vanin-1, an
oxidative stress sensor in epithelial cells, favors
production of inflammatory mediators, as recently
observed in a murine model. Thus, exposure of blood
mononuclear cells to oxidative stress inducers was
followed by upregulation of vannin-1 (VNN1), a gene
coding for an epithelial ectoenzyme with pantethei-
nase activity. Vannin-1 is a glycosylphosphatidylinosi-
tol (GPI)-linked molecule involved in the homing of
diverse cells and is currently put forward as a
biomarker for a variety of diseases.9 At the 4th ICIS
Expert Meeting, VNN1 was shown to be expressed
both during acute exacerbation and/or remission of
chronic ITP, but not in self-limited acute or resolved
acute ITP or in healthy controls.10 Oxidative damageof platelets may form the basis for earlier intervention
in selected groups of autoimmune disorders, such as
ITP,11 and, in fact, can be traced back to work
performed 10 years ago.12Infectious Events
End-organ apoptosis in progressive sepsis and
multiple organ dysfunction syndrome (MODS), espe-
cially where platelets accumulate (eg, spleen and
lung), may depend on microparticles shed from
platelets. Binding of the serine-rich repeat adhesion
of streptococci to human platelets via their sialyl-T
epitope on GPIba is thought to promote infective
endocarditis.13 Some bacteria might accelerate pla-
telet apoptosis or affect their function, but the
meeting focused on viral infection underscored by
the case report of a young female returning to
Switzerland from Thailand and affected with throm-
bocytopenia, soon to be confirmed as a complication
of Dengue fever infection.
Thrombocytopenia is indeed a frequent compli-
cation of viral infections. Multiple mechanisms are
involved depending on the nature of the viruses
involved and viral load. These include immunologic
platelet destruction, through formation of circulating
immune complexes (www.immune-complex.ch),
inappropriate platelet activation and consumption,
and impaired megakaryopoiesis. One the one hand,
HIV-1 viruses are internalized specifically in platelets
and megakaryocytes, where they can be sheltered,
ie, remain unaltered then ready for systemic spread
carried by platelets. On the other hand, it has been
observed that the chemokine receptor CXCL4 (PF-4),
an abundant protein contained within the a-granules
of platelets, blocks HIV-1 infection at the level of
virus attachment/entry through GP120 interaction.14
Chronic hepatitis C virus infections give rise to
systemic inflammation, ie, a mixed cryoglobulinemic
disease followed by severe vasculitis and thrombo-
cytopenia; platelets might be involved in severity
scores of hepatitis C liver disease.15
Measles/mumps/rubella (MMR) vaccination with
three live attenuated viruses may be followed by ITP
in childhood and adolescence.16 Other vaccines,
such as hepatitis A and tetanus-diphtheria-acellular-
pertussis might also rarely induce ITP. It was sug-
gested that those vaccines that cause ITP might be
identified by using genomics: would some children
be genetically susceptible? The US Food and
Drug Administration currently funds work to explain
why vaccines would kindle ITP; part of the projects,
such as family risk screening with GWAS, aims at
identifying newborns at risk using genetic tests. A
question from the auditorium as to whether one can
vaccinate a child with overt ITP was answered
with a yes.
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cines can be associated with autoimmune disease,
the culprit clearly to be sought in the adjuvant
portion of the vaccine. A current case-control study
in Italy is looking more closely at the hepatitis B
vaccine. The recently described ‘‘ASIA’’ syndrome
(autoimmune syndrome induced by adjuvants)17
complies with fatigue, a topic separately focused
on in Montreux; narcolepsy (chronic sleep disorder)
might indeed arise in patients developing specific
antibodies to adjuvants.18IMMUNOPATHOLOGICAL ENVIRONMENT OF
PLATELETS
The humoral portion of investigations into the
platelet environment since the last ICIS Expert Meeting
has allowed insight into cross reactivity of anti-platelet
with anti-viral antibodies, as well as antigenic mimicry
of antibodies against amino acids 49–66 on GPIIbIIIa.
Exploration of the epitope specificity to which auto-
antibodies bind has recently led to the discovery of
restricted regions in the b-propeller domain of alphaIIb,
suggesting that autoantibodies preferentially bind to the
b3 region of aIIb. Such findings are relevant to our
understanding of clonal expansion of platelet autoanti-
bodies and their anti-idiotypic downregulation.19–21
Anti-platelet autoantibodies activate Tc17 cells, leading
to antibody-mediated or cytotoxic T-cell platelet
destruction (Figure 1).22Figure 1. Platelets and the immune continuum. On this schem
such as to place the platelet participation in immune reactions
becomes aware of platelet involvement in inflammation as
Reproduced from Semple et al.45 Figure lent by Dr. Semple.
through the CCC.The more detailed understanding of innate immun-
ity, of which platelets form a part, and mouse experi-
ments, involving knockout mice, have renewed
interest in cellular immunologic backgrounds of
ITP. The Toronto Platelet Immunobiology Group
(www.stmichaelsfoundation.com) was also present
at this meeting. This link has focused interest on T
lymphocytes, and their regulatory interplay is now
being strongly linked to ITP. Regulatory T cells (Tregs)
expressing the FoxP3 transcription factor have a
profound and nonredundant role in many aspects of
immunologic tolerance (CD4þCD25 highFoxP3þ Tregs).
Tregs are dependent on interleukin (IL)-2 and IL-2
signaling to maintain their cell count and function;
interruption of this pathway promotes autoimmune
disease. The transcription factor Foxp3 is also
required for Treg function, as defective Foxp3 pro-
motes autoimmunity in both mice and humans.
Mouse models of ITP have brought Treg deficiencies
to light, since there is an overt thymic retention of
this cell type. In fact, peripheral Treg deficiencies,
due to such thymic retention and therapy, will
normalize the Treg; Tregs are also found in the B
cell area of lymph node germinal centers.23 In Treg-
deficient ITP mice, GPIb/IX is a major autoantigen.
Further to naturally occurring Tregs, there are also
adaptive Treg cells (‘‘educated’’ T cells) with identi-
cal phenotypes but with unique transcription factor
spectrum such as transforming growth factor beta
(TGF-b) and IL-10.atic drawing, acknowledged experiments are assembled
into perspective. Looking at the figure more closely, one
well as in innate and adaptive immune surveillance.
doi:10.1038/nri2956. Permission granted by NRI/NPG
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imately 10,000 platelets to 1 T cell, we may antici-
pate that the impact of Treg cells on platelet
homoeostasis is stark. Treg deficiency is very prom-
inent in patients with ITP and Treg count increases
in patients in remission.
Because of the now acknowledged presence of
impaired Treg function in ITP patients, its usefulness
as a biomarker for the disease is now being considered.
Moreover, therapeutic endeavors to improve its func-
tion would have a positive effect. Again, mouse models
have allowed Treg dysregulation to be linked to ITP
pathophophysiology, with at least one third of the
experimental animals developing bruises along with
anti-platelet aggression by Tregs.23
While CD4þCD25highFOX P3þ cells and the ratio
nTreg/iTreg (naturally occurring Tregs and induced
Tregs) have been evoked in detail, the immune cell
regulation has been carried further to the B-type
lymphocytes, which are now known to include
regulatory B cells.24 The participation of Tregs in
ITP awaits further research, certainly worth carrying
out, since B cells are cytokine-producing cells suit-
able for therapeutic concepts. The TNF ligand super-
family comprises a proliferation-inducing ligand
(APRIL) that shares binding to the TNF receptors
with soluble B-cell activation factor (BAFF); these
components are also gaining interest in the diagnosis
and clinical care of ITP patients. B-cell depletion for
those portions responsible for autoimmune disease
may indeed clear some forms of ITP, but the
homoeostasis of the Fcg receptor network must be
maintained to avoid conflicting results.25 BAFF, now
in focus for several autoimmune diseases, enhances
release of interferon-g, thus directly impinging on
the inflammatory equilibrium. BAFF binds to three
receptors—BAFF-R, TACI, and BCMA receptor—and
blocking experiments are underway.
Attempts have been made with possible correc-
tion of CD19þ cell apoptosis.
The effect of Toll-like receptor 7 (TLR7) and BAFF
was also studied in vitro using cell culture. Expres-
sion of TLR7 is increased in ITP and there exists a
significant correlation between TLR7 and BAFF.
According to findings from Israel, ITP and hepatitis
C virus infection ascertained their immunopatholog-
ical relation with patients of either diagnosis,
expressing high serum levels of BAFF.17 ITP thus
forms part of the mosaic of autoimmue disease, with
overlapping backgrounds and common therapeutic
approaches.
Functioning of the cytokine network in which
megakaryocytes and platelets evolve during acute or
chronic ITP broadens its net of checkpoints. At the
4th ICIS Expert Meeting, which someone dubbed
‘‘Gordon Conference of ITP,’’ focus was directed
toward IL-2, IL-10, and IL-17. In fact, FOXP3transcription factor is not expressed by a subtype
of Treg, but it is just this very same subtype that
produces IL-10 and TGF-b in response to antigenic
stimulation.26,27 This could be a checkpoint in the
way we develop ITP therapy and certainly needs to
be focused on in any therapeutic rationale. There-
fore, the question arose as to why platelets are so
commonly involved in autoimmune disease. The
logic here is broken down by the observation that
patients with common variable immunodeficiency
(CVID) may present with ITP but they lack anti-
platelet autoantibodies.
A hint may come from the now better-defined CD
coat of platelets shared with other cells of the
immune system, ie, CD9, CD23, CD31, CD49b,
CD61, and CD154. Natural killer (NK) cells like to
bind to platelets, mainly upon activation of the latter.
In this respect, one needs to realize that NK cells are
not just unspecific killing machines of innate immun-
ity, but that they undergo a process of education in
the medullary compartment. Release of granzyme
from NK cells assumes for crosstalk to dendritic cells
with their immediate engagement.27CLINICAL UPDATES
Medical Laboratory Diagnosis
Progress in routine laboratory technology has so
far contributed relatively few ground-breaking
advances in diagnosing ITP. Morphological assess-
ment of diseased platelets is more and more com-
pleted by flow cytometric techniques and bone
marrow smears. Serological tests for anti-platelet
antibodies, soluble immune-complexes, and BAFF
levels can be completed by thrombospondin and
thrombopoietin quantitation. This might be the
reason why one speaker proposed improving our
experiments with routine measurements of throm-
bopoietin in ITP. For the time being, molecular
biological tests remain in the background; they are
used for research protocols and so far have not
improved diagnosis or treatment protocols.
This may yet change with the rise of interest in
the unknown etiology of ITP, which might be
clarified using molecular biology tests, consisting of
a bioinformatic component with consensus primers
from amplimer libraries. Allele-specific oligonucle-
tide polymerase chain reaction (PCR) can thus be
used for high-throughput sequencing.28 Using such
platforms in Stanford, the pedigree of a family with
mild ITP (platelets nevero60,000/mL) over three
generations and treated with low-dose corticoste-
roids was found to carry mutations in ankyrin,
consistent with findings recently reported on nine
thrombocytopenia 2 (THC2) families in Italy.29 In
this project, with sequence coverages 45 and 42,
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3  106 mutations. Should similar findings arise in
other families, then the Molecular Diagnosis Labora-
tory at Stanford University Medical Center would
welcome any information. In children, there is clearly
a need to study their genetic background for ITP
predictors. Immunological laboratory protocols for
rheumatoid factor, anti-DNA antibodies, or comple-
ment system analyses, might blur clinical pictures that
point to ITP with simple platelet counts. Platelet
function tests, anti-platelet antibody assays, and
platelet-microparticle (they are hemostatically active)
workups have not reached the stage of ‘‘musts’’, the
more so as ITP patients have a normal aggregometry,
and p-selectin levels with sheer stress measurements
so far remain conflicting. However, it appears that the
size of aggregates is inversely correlated with bleeding
tendency. In New York, researchers are studying a
patient cohort with 25 chronic ITP patients, (14 male,
11 female) of whom 13 needed to be splenectomized.
The critical role of CD16þ monocytes, of which the
cell count negatively correlated with Tregs, is under-
lined by the recent finding that CD16þ ITP mono-
cytes promote expansion of IFN-gþCD4þ cells, and
concomitantly inhibit the proliferation of Tregs and
CD16þ monocytes.30 In other words, said one
speaker, ‘‘the more CD16 you have, the fewer Tregs
there are.’’ Because monocytes thereby trigger plate-
let responses, the researchers have now set up an
anti-CD3 stimulation assay, the results of which might
be ready for the next ICIS meeting.Clinical Features of ITP
Clinical and laboratory diagnosis of ITP was
assumed to be familiar to the participants, the more
so as the American Society of Hematology (ASH)
Hematology Clinical Practice Guidelines and the
European Hematology Association (EHA) Guidelines
are globally accepted (www.hematology.org, www.
ehaweb.org). Therefore, the meeting emphasized
pathogenesis and new treatments of ITP. This is not
to say that seemingly simple features of the disease,
such as the bleeding signs, a leading indicator in ITP,
would not require attention. Some participants
addressed this sign: in non-bleeders, it may be hidden
in internal organs apart from mucosae and skin
(occult hemorrhage). The tendency to bleed does
not unequivocally relate to the platelet count. Record
keeping of hemorrhages remains an often neglected
aspect in the diagnosis and follow-up of ITP. Doc-
umentation of intracranial and retinal hemorrhage
may be missed by non-ophthalmologists. Brain mag-
netic resonance imaging may be necessary to spot
microhemorrhagic lesions, in the absence of evi-
dence of a head trauma and, in this respect, a simpler
diagnostic tool to predict hemorrhage would bewelcome. Therefore, the Dallas team has initiated a
prospective ITP cohort registry with structured
follow-up visits, at least 6 months after initial treat-
ment was begun. Underreporting of hemorrhage in
ITP also includes gastrointestinal bleeds; hematuria
occurs but only in severe cases. The last ‘‘classical’’
bleeding score paper dates back 5 years,31 but one
participant felt its message should remain in use
during clinical studies with new therapeutic agents.
ITP is increasingly seen in adults and may present
with fatigue independently associated with a platelet
counto30,000/mL or other medical conditions, day-
time sleepiness, and orthostatic symptoms.32 The
relationship between fatigue and ITP is not under-
stood and, as one participant noted, perhaps bridges
over the cytokine network. Diagnosis of autoim-
mune lymphoproliferative syndrome (ALPS; lympha-
deopathy, hepatosplenomegaly, and autoimmune
cytopenias) has to be considered in patients affected
with chronic thrombocytopenia.33Therapeutic Update
Ever since Imbach’s observation of the life-saving
efficacy of intravenous immunoglobulin (IVIG) trans-
fusion,34 further insights into IVIG on its own35 were
not discussed at the ICIS Meeting. Until now, older
treatment protocols have been scrutinized, most
prominently the value of splenectomy, which remains
controversial, even in an era where fusion proteins
and biosimilar agents have further revolutionized ITP
treatment. Evidence-based indications for laparo-
scopic splenectomy are still lacking, the potential
for spontaneous recovery of ITP remaining a major
argument against it. Splenectomy or other interven-
tions with potentially serious complications should be
delayed for at least 6–12 months, unless the ITP is
accompanied by severe disease defined by the Inter-
national Working Group criteria, unresponsive to
other measures or other quality-of-life considerations
(grade 2C).36 Among pediatric patients, 70%–80%
with ITP will recover by 6–12 months, as the experts
from the Schneider Children’s Medical Center put
forward, in agreement with the Nordic Score, which
even gives credit to recovery within 3 months of a
quarter of all ITP incidences. It is still unclear whether
molecular biologic tests could predict hope for
remission, with such clinical background as age/
symptoms/previous infection/mucosal bleeding/plate-
let count as the mainstays of score evaluations.
Surprisingly, cannabinoid receptors CB1 and CB237
have recently been put forward for genetic testing of
ITP, but their importance for patient care awaits
further exploration.
The second- and third-line therapies were separately
addressed and the audience soon realized that the
various rationales from translational protocols have
U.E. Nydegger and L. RischS8not allowed the pursuit of a unique path. With cortico-
steroid treatment likely to impinge on Tregs,38 drugs
that target selected components of the immune
system, like rituximab (chimeric monoclonal anti-
body against the protein CD20), are also used
tentatively in ITP; one speaker reported a favorable
effect on Tregs,39 but further basic research is
necessary to elucidate the spectrum of the therapeu-
tic B-cell CD20 blockade, which is so successful in
lymphoproliferative disorders.40
With elderly ITP patients (one male patient cited
at the Montreux Meeting was 92 years old), a new
cohort arises that requires anticoagulation for those
patients recovering from vascular occlusion disease.
There exists experience with vitamin K antagonists,
albeit factor Xa- and thrombin-inhibitors (rivaroxa-
ban and dabigatranexilate), but these agents have
not yet been licensed for such situations.41
Promising data were updated in Montreux with
thrombopoietin receptor agonists (TRAs) like Romi-
plostim. The tertiary structure of this fusion protein
analog of the hormone thrombopoietin was shown
to the participants, and speakers confirmed that
TRAs engage the intracellular signaling cascade, just
the same way as native thrombopeoietin does.
Eltrombopag is a small molecule agonist of the
c-mpl (TpoR) receptor, which is the physiological
target of thrombopoietin, and is now acknowledged
for its multilineage response in hematopoiesis. For-
mulations for once daily dosing are in the limelight
of therapists. Further to elevating low platelet
counts, the drug leads to hemostasis within as few
as 5 days, probably through receptor engagement on
vascular endothelial cells, which is why surgeons are
interested in the ability of these new drugs42 to
reduce red blood cell concentrate transfusion
dependency.
For the care of ITP, discussions at the 4th ICIS
meeting revolved around the possibility of using
biosimilar agents as first-line therapy.FINAL REMARKS
Translational researchers often forget to discuss
the costs of novel treatments. A brief remark was
made in Montreux by speakers for the Boston Child-
ren’s Hospital, Boston, MA, which uses Standardized
Clinical Assessment and Management Plans (SCAMPs).
In children who are unable to explain their suffering,
elaborate testing is often needed for diagnosis. Clini-
cians need flexible, evidence-based standards that
improve sometimes obsolete clinical practice guide-
lines, as well as evidence-based recommendations for
care while decreasing overutilization of resources.
Providing children and their families with an optimal
quality of life was an issue felt throughout the
Montreux meeting and it was addressed morespecifically in the concluding discussions. The esti-
mation of individual bleeding risk, similarly as with
hemophilia patients, and the heterogeneity of patho-
physiology at the origin of personalized medicine and
individual treatments, not least the watch-and-wait
strategy, were related to ITP. Child self-reported
scores and case comparisons on an international
level will make quality-of-life programs more pre-
cise.43,44 The 4th ICIS has paved the way for
continuing in the right direction.Acknowledgments
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